학술논문

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial
Document Type
Article
Author
Datoo, Mehreen SDicko, AlassaneTinto, HalidouOuédraogo, Jean-BoscoHamaluba, MaingaOlotu, AllyBeaumont, EmmaRamos Lopez, FernandoNatama, Hamtandi MagloireWeston, SophieChemba, MwajumaCompaore, Yves DanielIssiaka, DjibrillaSalou, DialloSome, Athanase MOmenda, SharonLawrie, AlisonBejon, PhilipRao, HarishChandramohan, DanielRoberts, RachelBharati, SandeshStockdale, LisaGairola, SunilGreenwood, Brian MEwer, Katie JBradley, JohnKulkarni, Prasad SShaligram, UmeshHill, Adrian V SMahamar, AlmahamoudouSanogo, KoualySidibe, YoussoufaDiarra, KalifaSamassekou, MamoudouAttaher, OumarTapily, AmadouDiallo, MakononDicko, Oumar MohamedKaya, MahamadouMaguiraga, Seydina OumarSankare, YayaYalcouye, HamaDiarra, SoumailaNiambele, Sidi MohamedThera, IsmailaSagara, IssakaSylla, MalaDolo, AmaganaMisidai, NsajigwaSimando, SylvesterMsami, HaniaJuma, OmaryGutapaka, NicolausPaul, RoseMswata, SarahSasamalo, IbrahimJohaness, KasmirSultan, MwantumuAlexander, AnnastaziaKimaro, IsaacLwanga, KauyeMtungwe, MwajumaKhamis, KassimRugarabam, LightonKalinga, WilminaMohammed, MohammedKamange, JanethMsangi, JubilateMwaijande, BatuliMtaka, IvannyMhapa, MatildaMlaganile, TarsisMbaga, ThabitYerbanga, Rakiswende SergeSamtouma, WendkouniSienou, Abdoul AzizKabre, ZachariOuedraogo, Wendinpui Jedida MurielYarbanga, G Armel BienvenuZongo, IssakaSavadogo, HamadeSanon, JosephCompaore, JudicaelKere, IdrissaYoni, Ferdinand LionelSanre, Tewende MartineOuattara, Seydou BienvenuProvstgaard-Morys, SamuelWoods, DanielleSnow, Robert W.Amek, NyaguaraNgetsa, Caroline J.Ochola-Oyier, Lynette IsabellaMusyoki, JenniferMunene, MarianneMumba, NoniAdetifa, Uche JaneMuiruri, Charles MwangiMwawaka, Jimmy ShangalaMwaganyuma, Mwatasa HusseinNdichu, Martha NjeriWeya, Joseph OchiengNjogu, KelvinGrant, JaneWebster, JayneLakhkar, AnandIdo, N. Félix AndréTraore, OusmaneTahita, Marc ChristianBonko, Massa dit AchilleRouamba, ToussaintOuedraogo, D. FlorenceSoma, RachidatouMillogo, AidaOuedraogo, EdouardSorgho, FaizatouKonate, FabéValea, Innocent
Source
The Lancet; February 2024, Vol. 403 Issue: 10426 p533-544, 12p
Subject
Language
ISSN
01406736; 1474547X
Abstract
Recently, we found that a new malaria vaccine, R21/Matrix-M, had over 75% efficacy against clinical malaria with seasonal administration in a phase 2b trial in Burkina Faso. Here, we report on safety and efficacy of the vaccine in a phase 3 trial enrolling over 4800 children across four countries followed for up to 18 months at seasonal sites and 12 months at standard sites.